These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 25394052)

  • 21. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
    Flammer AJ; Vo NT; Ledergerber B; Hermann F; Gämperli A; Huttner A; Evison J; Baumgartner I; Cavassini M; Hayoz D; Quitzau K; Hersberger M; Sudano I; Ruschitzka F; Lüscher TF; Noll G; Weber R
    Heart; 2009 Mar; 95(5):385-90. PubMed ID: 18653575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
    Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
    J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors.
    Barber TJ; Moyle G; Hill A; Singh GJ; Boffito M; Nelson M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19827. PubMed ID: 25397571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between Endothelial Function, Antiretroviral Treatment and Cardiovascular Risk Factors in HIV Patients of African Descent in South Africa: A Cross-Sectional Study.
    Nkeh-Chungag BN; Goswami N; Engwa GA; Sewani-Rusike CR; Mbombela V; Webster I; De Boever P; Kessler HH; Stelzl E; Strijdom H
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33498530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of antiretroviral therapy on cardiac risk markers in people living with HIV/AIDS.
    Gupta PK; Tyagi S; Sheoran A; Jain P; Koner SK; Sharma LK; Singh SK; Khura J
    Indian J Sex Transm Dis AIDS; 2022; 43(1):52-55. PubMed ID: 35846544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy.
    Lembas A; Zawartko K; Sapuła M; Mikuła T; Kozłowska J; Wiercińska-Drapało A
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urolithiasis Develops Endothelial Dysfunction as a Clinical Feature.
    Sáenz-Medina J; Martinez M; Rosado S; Durán M; Prieto D; Carballido J
    Antioxidants (Basel); 2021 May; 10(5):. PubMed ID: 34064366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular dysfunction and cardiovascular complications.
    Triant VA; Grinspoon SK
    Curr Opin HIV AIDS; 2007 Jul; 2(4):299-304. PubMed ID: 19372902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal evaluation of markers of inflammation in HIV-positive and HIV-negative Rwandan women.
    Kiefer EM; Hoover DR; Shi Q; Dusingize JC; Sinayobye JD; Anastos K
    HIV Med; 2018 Nov; 19(10):734-744. PubMed ID: 30160347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection.
    Kirichenko TV; Myasoedova VA; Shimonova TE; Melnichenko AA; Sviridov D; Sobenin IA; Mazus AI; Orekhov AN; Bukrinsky MI
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29961673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continued Interest and Controversy: Vitamin D in HIV.
    Hsieh E; Yin MT
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):199-211. PubMed ID: 29713871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocyte/macrophages and their role in HIV neuropathogenesis.
    Burdo TH; Lackner A; Williams KC
    Immunol Rev; 2013 Jul; 254(1):102-13. PubMed ID: 23772617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epi-aortic lesions, pathologic FMD, endothelial activation and inflammatory markers in advanced naïve HIV-infected patients starting ART therapy.
    Bellacosa C; Maggi P; Volpe A; Altizio S; Ladisa N; Cicalini S; Viglietti R; Chirianni A; Bellazzi L; Zanaboni D; Maserati R; Martinelli C; Corsi P; Sofia S; Celesia M; Sozio F; Abbrescia N; Angarano G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19545. PubMed ID: 25394052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
    Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
    Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection.
    Guimarães MM; Greco DB; Figueiredo SM; Fóscolo RB; Oliveira AR; Machado LJ
    Atherosclerosis; 2008 Dec; 201(2):434-9. PubMed ID: 18359028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.